Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.65 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434800 | 1.00 | FFAR1 (0.65) | FFAR1MMP12ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL434798 | 0.92 | FFAR1 (0.60) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL434797 | 0.92 | FFAR1 (0.60) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL433312 | 0.90 | FFAR1 (0.66) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL433313 | 0.90 | FFAR1 (0.66) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL10258785 | 0.89 | FFAR1 (0.65) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL435055 | 0.89 | FFAR1 (0.57) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL435054 | 0.89 | FFAR1 (0.57) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL10259328 | 0.88 | FFAR1 (0.64) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL22668454 | 0.88 | FFAR1 (0.65) | FFAR1ALDH1A1HTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | FFAR1 24/4885MMP12 3759/4885ALDH1A1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.